Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their N-glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. Physcomitrella (Physcomitrium patens, moss) is able to perform highly homogeneous complex-type N-glycosylation. Additionally, it has been glyco-engineered to eliminate plant-specific sugar residues by knock-out of the β1,2-xylosyltransferase and α1,3-fucosyltransferase genes (Δxt/ft). Furthermore, P. patens meets wide-ranging biopharmaceutical requirements such as GMP compliance, product safety, scalability and outstanding possibilities for precise genome engineering.

中文翻译：

---

假单胞菌中稳定的蛋白质唾液酸化

重组产生的蛋白质是医疗应用中必不可少的工具。由于它们中的大多数是糖蛋白，因此它们的N-糖基化曲线是决定其活性，结构性质和安全性的主要因素。对于治疗应用，适合于产品和治疗要求的糖基化模式是有利的。假单胞菌（Physcomitrium patens，苔藓）能够进行高度均一的复合型N-糖基化。此外，它已被糖工程化，可通过敲除β1,2-木糖基转移酶和α1,3-岩藻糖基转移酶基因（Δxt/ ft）消除植物特有的糖残基。此外，P。patens 满足广泛的生物制药要求，例如符合GMP，产品安全性，可扩展性以及精确基因组工程的出色可能性。